Metabolic Myoglobinuria

Current Neurology and Neuroscience Reports

Volumn 15, Issue 10, 2015, Pages

  Barca, Emanuele ^a,b,c   Emmanuele, Valentina ^a  

^a Howard Hughes Medical Institute   (United States)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d Billi)   (United States)

Author keywords

ATP shortage; Fatty acid oxidation (FAO); Mitochondrial myopathies; Muscle glycogenoses; Myoglobinuria treated with hydration or renal dialysis; Uncertain therapy for metabolic myopathies

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ACYL COENZYME A DEHYDROGENASE; ADENOSINE TRIPHOSPHATE; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE II; CREATINE KINASE; FRUCTOSE BISPHOSPHATE ALDOLASE; GLYCOGEN; GLYCOGEN SYNTHASE; IRON SULFUR CLUSTER SCAFFOLD PROTEIN; IRON SULFUR PROTEIN; LACTATE DEHYDROGENASE; LONG CHAIN FATTY ACID; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN; MYOGLOBIN; PHOSPHATIDATE PHOSPHATASE; PHOSPHOGLUCOMUTASE; PHOSPHOGLYCERATE KINASE; PHOSPHORYLASE; PHOSPHORYLASE KINASE; RYANODINE RECEPTOR 1; UBIDECARENONE; UNCLASSIFIED DRUG; VERY LONG CHAIN ACYL COENZYME A DEHYDROGENASE;

AUTOSOMAL DOMINANT DISORDER; COMPARTMENT SYNDROME; COMPLEX III DEFICIENCY; CYTOCHROME C OXIDASE DEFICIENCY; DIFFERENTIAL DIAGNOSIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXERCISE; GENE MUTATION; GLYCOGEN METABOLISM; GLYCOGEN STORAGE DISEASE TYPE 5; GLYCOGEN STORAGE DISEASE TYPE 7; HUMAN; METABOLIC DISORDER; METABOLIC MYOGLOBINURIA; MITOCHONDRIAL MYOPATHY; MITOCHONDRIAL RESPIRATION; MOLECULAR GENETICS; MUSCLE BIOPSY; MYOGLOBINURIA; MYOPATHY; RADIOIMMUNOASSAY; REVIEW; RHABDOMYOLYSIS; BIOSYNTHESIS; COMPLICATION; METABOLISM; MITOCHONDRION; MUSCLE DISEASE; RENAL REPLACEMENT THERAPY;

ADENOSINE TRIPHOSPHATE; GLYCOGEN; HUMANS; MITOCHONDRIA; MUSCULAR DISEASES; MYOGLOBINURIA; RENAL DIALYSIS;

EID: 84940665652     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-015-0590-9     Document Type: Review

References (75)

1. Hed R, Larsson H, Wahlgren F. Acute myoglobinuria: report of a case with fatal outcome. Acta Med Scand. 1955;152:959–63.
2. Mochel F, Knight MA, Tong W-H, et al. Splice mutation in the iron-sulfur cluster scaffold protein ISCU causes myopathy with exercise intolerance. Am J Hum Genet. 2008;82:652–60.
3. Kagen LJ. Myoglobin: biochemical, physiological, and clinical aspects. New York: Columbia University Press; 1973.
4. Bywaters EG. Ischemic muscle necrosis. JAMA. 1944;124.
5. Kanno T, Sudo K, Maekawa M, Nishimura Y, Ukita M, Fukutaka K. Lactate dehydrogenase M-subunit deficiency: a new type of hereditary exertional myopathy. Clin Chim Acta. 1988;173:89–98.
6. Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci U S A. 1989;86:2379–82.
7. Sobreira C, Hirano M, Shanske S, et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology. 1997;48:1238–43.
8. Di Giovanni S, Mirabella M, Spinazzola A, et al. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology. 2001;57:515–8.
9. Angelini C, Fanin M, Pegoraro E, Freda MP, Cadadini M, Martinello F. Clinical-molecular correlation in 104 mild X-linked muscular dystrophy patients: characterization of sub-clinical phenotypes. Neuromuscul Disord. 1994;4:349–58.
10. Garrood P, Eagle M, Jrdine PE, Straub V. Myoglobinuria in boys with Duchenne muscular dystrophy on corticosteroid therapy. Neuromuscul Disord. 2008;18:71–3.
11. Pena L, Kim K, Charow J. Episodic myoglobinuria in a primary gamma-sarcoglycanopathy. Neuromuscul Disord. 2010;20:337–9.
12. Cagliani R, Comi GP, Tancredi L, et al. Primary beta-sarcoglycanopathy manifesting as recurrent exercise-induced myoglobinuria. Neuromuscul Disord. 2001;11:389–94.
13. Lindberg C, Sixt C, Oldfors A. Episodes of exercise-induced dark urine and myalgia in LGMD 21. Acta Neurol Scand. 2012;125:285–7.
14. Aboumousa A, Hoogendijk JE, Charlton R, et al. Caveolinopathy—new mutations and additional symptoms. Neuromuscul Disord. 2008;18:572–8.
15. Lahoria R, Winder TL, Lui J, Al-Qwain MA, Milone M. ANO5 homozygous microdeletion causing myalgia and unprovoked rhabdomyolysis in an Arabic man. 2014;50:610–3.
16. Dlamini N, Voermans NC, Lillis S, et al. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscul Disord. 2013;23:540–8. Dlamini and numerous European colleagues report an onslaught of patients with exercise-induced but often unprovoked episodes of myoglobinuria due to mutations in the ryanodine receptor 1 gene (RYR1). These frequent patients distract attention from patients with metabolic myoglobinuria and, more often than not, from patients with malignant hyperthermia (MH).
17. Bricker DK, Taylor EB, Schell JC, et al. A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science. 2012;337:96–100.
18. McArdle B. Myopathy due to a defect in muscle glycogen breakdown. Clin Sci. 1951;10:13–33.
19. DiMauro S, Arnold S, Miranda AF, Rowland LP. McArdle disease: the mystery of reappearing phosphorylase activity in muscle culture. A fetal isoenzyme. Ann Neurol. 1978;3:60–6.
20. Roelofs RI, Engel WK, Chauvin PB. Histochemical phosphorylase activity in regenerating muscle fibers from myophosphorylase-deficient patients. Science. 1967;177:795–7.
21. Mitsumoto H. McArdle disease: phosphorylase activity in regenerating muscle fibers. Neurology. 1979;29:258–62.
22. Preisler N, Orngreen MC, Echaniz-Laguna A, et al. Muscle phosphorylase kinase deficiency. A neutral metabolic variant or a disease? Neurology. 2012;78:265–8. Preisler et al. call attention to phosphorylase b kinase (PhK) deficiency, which cannot simulate McArdle disease by failing to produce flat ischemic forearm exercise or to show second wind, but increasing muscle glycogen and by causing in men exercise-related myalgia and occasional myoglobinuria.
23. Stojkovic T, Vissing J, Petit F, et al. Muscle glycogenosis due to phosphoglucomutase 1 deficiency. N Engl J Med. 2009;361:425–7.
24. Haller RG, Lewis SF. Glucose-induced exertional fatigue in muscle phosphofructokinase deficiency. N Engl J Med. 1991;324:364–9.
25. Haller RG, Vissing J. No spontaneous second wind in muscle phosphofructokinase deficiency. Neurology. 2004;62:82–6.
26. Argov Z, Bank WJ. Phosphorus magnetic resonance spectroscopy (31P MRS) in neuromuscular disorders. Ann Neurol. 1991;30:90–7.
27. Agamanolis DP, Askari AD, DiMauro S, et al. Muscle phosphofructokinase deficiency: two cases with unusual polysaccharide accumulation and immunologically active enzyme protein. Muscle Nerve. 1980;3:456–67.
28. Raben N, Danon MJ, Lu N, et al. Surprises of genetic engineering: a possible model of polyglucosan body disease. Neurology. 2001;56:1739–45.
29. Kreuder J, Borkhardt A, Repp R, et al. Inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. N Engl J Med. 1996;334:1100–4.
30. Yao DC, Tolan DR, Murray MF, et al. Hemolytic anemia and severe rhabdomyolysis caused by compound heterozygous mutations of the gene for erythrocyte/muscle isozyme of aldolase. Blood. 2004;103:2401–3.
31. Spiegel R, Area Gomez E, Akman HO, Krishna S, Horovitz Y, DiMauro S. Myopathic form of phosphoglycerate kinase (PGK) deficiency: a new case and pathogenic considerations. Neuromuscul Disord. 2009;19:207–11.
32. Sotiriou E, Greene P, Krishna S, Hirano M, DiMauro S. Myopathy and Parkinsonism in phosphoglycerate kinase deficiency. Muscle Nerve. 2010;41:707–10.
33. DiMauro S, Spiegel R. Progress and problems in muscle glycogenoses. Acta Myol. 2011;30:96–102.
34. Kanno T, Sudo K, Takeuchi I, et al. Hereditary deficiency of lactate dehydrogenase M-subunit. Clin Chim Acta. 1980;108:267–76.
35. Maekawa M, Sudo K, Kanno T, Li S. Molecular characterization of genetic mutation in human lactate dehydrogenase-A (M) deficiency. Biochem Biophys Res Commun. 1990;168:677–82.
36. Maekawa M, Sudo K, Kanno T, et al. A novel mutation of lactate dehydrogenase A (M) gene in the fifth family with the enzyme deficiency. Hum Mol Genet. 1994;3:825–6.
37. Maekawa M, Sudo K, Li S, Kanno T. Analysis of genetic mutation in human lactate dehydrogenase-A (M) deficiency using DNA conformation polymorphism in combination with polyacrilamide gradient gel and silver staining. Biochem Biophys Res Commun. 1991;180:1083–90.
38. Tsujino S, Shanske S, Brownell A, Haller RG, DiMauro S. Molecular genetic studies of muscle lactate dehydrogenase deficiency in white patients. Ann Neurol. 1994;36:661–5.
39. Kollberg G, Tulinius M, Gilljam T, et al. Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. N Engl J Med. 2007;357:1507–14.
40. Cameron JM, Levandovskiy V, MacKay N, et al. Identification of a novel mutation in GSY1 (muscle-specific glycogen synthase) resulting in sudden cardiac death, that is diagnosable from skin fibroblasts. Mol Genet Metab. 2009;98:378–82.
41. Sukigara S, Liang W-C, Komaki H, et al. Muscle glycogen storage disease 0 presenting recurrent syncope with weakness and myalgia. Neuromuscul Disord. 2012;22:162–5. Sukigara and coworkers illustrate a typical presentation of glycogen synthetase (GS1) deficiency, and lack of glycogen simulates a block of glycogenolysis with excessive glycogen (e.g., McArdle disease). Lack of a central muscle fuel impairs ATP production, increases mitochondrial abundance, and—paradoxically—gives a negative phosphorylase histochemical reaction.
42. DiMauro S, DiMauro-Melis PM. Muscle carnitine palmityltransferase deficiency and myoglobinuria. Science. 1973;182:929–31.
43. Bank WJ, DiMauro S, Bonilla E, Capuzzi DM, Rowland LP. A disorder of muscle lipid metabolism and myoglobinuria. Absence of carnitine palmityltransferase. N Engl J Med. 1975;292:443–9.
44. Britton CH, Schultz RA, Zhang B, Esser V, Foster DW, McGarry JD. Human liver mitochondrial carnitine palmitoyltransferase I: characterization of its cDNA and chromosomal localization and partial analysis of the gene. Proc Natl Acad Sci U S A. 1995;92:1984–8.
45. Gellera C, Verderio E, Floridia G, et al. Assignment of the human carnitine palmitoyltransferase II gene (CPT1) to chromosome 1p32. Genomics. 1994;24:195–7.
46. Tonin P, Lewis P, Servidei S, DiMauro S. Metabolic causes of myoglobinuria. Ann Neurol. 1990;27:181–5.
47. DiDonato S, Taroni F. Disorders of lipid metabolism. In: Engel AG, Franzini-Armstrong C, editors. Myology. New York: McGraw-Hill; 2004. p. 1587–621.
48. Kaufmann P, El-Schahawi M, DiMauro S. Carnitine palmitoyltransferase II deficiency: diagnosis by molecular analysis of blood. Mol Cell Biochem. 1997;174:237–9.
49. Montermini L, Wang H, Verderio E, Taroni F, DiDonato S, Finocchiaro G. Identification of 5′ regulatory regions of the human carnitine palmitoyltransferase II gene. Biochim Biophys Acta. 1994;1219:237–40.
50. Roe CR, Yang B-Z, Brunengraber H, Roe DS, Wallace M, Garritson BK. Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology. 2008;71:260–4.
51. Bonnefont J-P, Bastin J, Behin A, Djouadi F. Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med. 2009;360:838840.
52. Ohashi Y, Hasegawa Y, Murayama K, et al. A new diagnostic test for VLCAD deficiency using immunohistochemistry. Neurology. 2004;62:2209–13.
53. Laforet P, Acquaviva-Bourdain C, Rigal O, et al. Diagnostic assessment and long-term follow-up of 13 patients with very long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency. Neuromuscul Disord. 2009;19:324–9.
54. Laforet P, Vianey-Saban C. Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges. Neuromuscul Disord. 2010;20:693–700.
55. DiMauro S. Mitochondrial myopathies. Curr Opin Rheumatol. 2006;18:636–41.
56. Andreu AL, Hanna MG, Reichmann H, et al. Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med. 1999;341:1037–44.
57. Emmanuele V, Sotiriou E, Gutierrez Rios P, et al. A novel mutation in the mitochondrial DNA cytochrome b gene (MTCYB) in a patient with MELAS syndrome. J Child Neurol. 2013;28:236–42. Emmanuele et al. showed a case of MELAS (mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes) syndrome in a girl with a rare MTCYB mutation, which is more often associated with sporadic myopathy, exercise intolerance, and often myoglobinuria.
58. Keightley JA, Hoffbuhr KC, Burton MD, et al. A microdeletion in cytochrome c oxidase (COX) subunit III associated with COX deficiency and recurrent myoglobinuria. Nat Genet. 1996;12:410–5.
59. Karadimas CL, Greenstein P, Sue CM, et al. Recurrent myoglobinuria due to a nonsense mutation in the COX I gene of mtDNA. Neurology. 2000;55:644–9.
60. Kollberg G, Moslemi A-R, Lindberg C, Holme E, Oldfors A. Mitochondrial myopathy and rhabdomyolysis associated with a novel nonsense mutation in the gene encoding cytochrome c oxidase subunit I. J Neuropathol Exp Neurol. 2005;64:123–8.
61. McFarland R, Taylor RW, Chinnery PF, Howell N, Turnbull DM. A novel sporadic mutation in cytochrome c oxidase subunit II as a cause of rhabdomyolysis. Neuromuscul Disord. 2004;14:162–6.
62. Haller RG, Henriksson KG, Jorfeldt L, et al. Deficiency of skeletal muscle succinate dehydrogenase and aconitase. J Clin Invest. 1991;88:1197–206.
63. Hall RE, Henriksson KG, Lewis SF, Haller RG, Kennaway NG. Mitochondrial myopathy with succinate dehydrogenase and aconitase deficiency. Abnormalities of several iron-sulfur proteins. J Clin Invest. 1993;92:2660–6.
64. Kollberg G, Melberg A, Holme E, Oldfors A. Transient restoration of succinate dehydrogenase activity after rhabdomyolysis in iron-sulfur cluster deficiency myopathy. Neuromuscul Disord. 2010;21:115–20.
65. DiGiovanni S, Mirabella M, Papacci M, Odoardi F, Silvestri G, Servidei S. Apoptosis and ROS detoxification enzymes correlate with cytochrome c oxidase deficiency in mitochondrial encephalomyopathies. Mol Cell Neurosci. 2001;17:696–705.
66. Lalani S, Vladutiu GD, Plunkett K, Lotze TE, Adesina AM, Scaglia F. Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency. Arch Neurol. 2005;62:317–20.
67. Aure K, Benoist JF, Ogier de Baulny H, Romero NB, Rigal O, Lombes A. Progression despite replacement of a myopathic form of coenzyme Q10 defect. Neurology. 2004;63:727–9.
68. Horvath R, Scneiderat P, Schoser BGH, et al. Coenzyme Q10 deficiency and isolated myopathy. Neurology. 2006;66:253–5.
69. Gempel K, Topaloglu H, Talim B, et al. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain. 2007;130:2037–44.
70. Liang W-C, Ohkuma A, Hayashi YK, et al. ETFDH mutations, CoQ10 levels, and respiratory chain activities in patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. Neuromuscul Disord. 2009;19:212–6.
71. Ohkuma A, Noguchi S, Sugie H, et al. Clinical and genetic analysis of lipid storage myopathies. Muscle Nerve. 2009;39:333–42.
72. Tein I, DiMauro S, DeVivo DC. Recurrent childhood myoglobinuria. Adv Pediatr. 1990;37:77–117.
73. Zeharia A, Shaag A, Houtkooper RH, et al. Mutations in LPIN cause recurrent childhood myoglobinuria in childhood. Am J Hum Genet. 2008;83:489–94.
74. Rowland LP, Araki S, Carmel P. Contracture in McArdle’s disease. Arch Neurol. 1965;13:541–4.
75. Haller RG, Vissing J. Functional evaluation of metabolic myopathies. In: Engel AG, Franzini-Armstrong C, editors. Myology. New York: McGraw-Hill; 2004. p. 665–79.